Patients as experts: characterizing the most relevant patient-reported outcomes after hematopoietic cell transplantation

Solle, Justin Cook; Steinberg, Alexis; Marathe, Priya; Gray, Tamryn F.; Emmert, Amy; Abel, Gregory A.

doi:10.1038/s41409-019-0518-0

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is a formal method of working with experts to achieve consensus, involving several rounds of assessments, presentation of interim results, and expert discussion between rounds. After a review of high-quality modified Delphi studies [15][16][17], and consistent with modified Delphi analyses of similar blood cancer questions [18], we aimed for a predetermined consensus level of 75% agreement among our expert panelists. Participants in our panel were recruited from the roster of MDS experts attending the March 2018 Aplastic Anemia and MDS International Foundation (AAMDSIF) Bone Marrow Failure Disease Scientific Symposium.…”

Section: Methodsmentioning

confidence: 99%

Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Tanasijevic

Revette

Klepin

et al. 2020

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher.

show abstract

Section: Methodsmentioning

confidence: 99%